Low-Dose Hyperradiosensitivity: Is There a Place for Future Investigation in Clinical Settings?

In our experience, concurrent LD-FRT and chemotherapy was well tolerated. Because the response rate seems promising, prospective Phase II studies of the strategy are now under way.